Post reply

The message has the following error or errors that must be corrected before continuing:
Warning: this topic has not been posted in for at least 365 days.
Unless you're sure you want to reply, please consider starting a new topic.
Other options
Verification:
Please leave this box empty:
Type the letters shown in the picture
Listen to the letters / Request another image

Type the letters shown in the picture:
Three blonde, blue-eyed siblings are named Suzy, Jack and Bill.  What color hair does the sister have?:
Please spell spammer backwards:
Shortcuts: ALT+S post or ALT+P preview

Topic summary

Posted by CMdeux
 - February 27, 2013, 11:20:19 AM
http://www.jacionline.org/article/S0091-6749%2812%2902692-9/fulltext


The upshot:

Quote
Meticulous care is taken by our omalizumab administration clinic to ensure optimal safety based on the emphasized warnings of anaphylaxis. Data collected in this analysis observed no cases of anaphylaxis in the treatment of over 200 patients, during a period of 14 years, who combined received 20,000 injections of omalizumab.

This is great news, since the FDA has estimated an anaphylaxis rate of about 0.2% with Xolair-- a finding which may be too high, it seems.